Phillips 66 Partners LP (PSXP) At $46.01 Forms Bottom; CR Bard (BCR) SI Increased By 8.9%

December 7, 2017 - By Stephen Andrade

Phillips 66 Partners LP (PSXP) formed multiple bottom with $44.63 target or 3.00% below today’s $46.01 share price. Phillips 66 Partners LP (PSXP) has $5.59 billion valuation. The stock decreased 2.95% or $1.4 during the last trading session, reaching $46.01. About 176,115 shares traded. Phillips 66 Partners LP (NYSE:PSXP) has declined 0.26% since December 7, 2016 and is downtrending. It has underperformed by 16.96% the S&P500.

CR Bard Incorporated (NYSE:BCR) had an increase of 8.9% in short interest. BCR’s SI was 1.22 million shares in December as released by FINRA. Its up 8.9% from 1.12M shares previously. With 414,400 avg volume, 3 days are for CR Bard Incorporated (NYSE:BCR)’s short sellers to cover BCR’s short positions. The SI to CR Bard Incorporated’s float is 1.7%. The stock decreased 0.11% or $0.35 during the last trading session, reaching $332.14. About 811,572 shares traded or 66.61% up from the average. C. R. Bard, Inc. (NYSE:BCR) has risen 40.70% since December 7, 2016 and is uptrending. It has outperformed by 24.00% the S&P500.

Investors sentiment decreased to 1 in 2017 Q2. Its down 0.51, from 1.51 in 2017Q1. It worsened, as 12 investors sold Phillips 66 Partners LP shares while 43 reduced holdings. 13 funds opened positions while 42 raised stakes. 42.11 million shares or 3.45% more from 40.71 million shares in 2017Q1 were reported. Signature Financial Management owns 4,100 shares for 0.06% of their portfolio. Jpmorgan Chase holds 0.01% or 636,286 shares in its portfolio. Hightower Llc invested in 79,959 shares. Miller Howard Investments Incorporated New York holds 517,942 shares or 0.51% of its portfolio. Tortoise Capital Advsr Lc reported 8.03 million shares. 122,600 were reported by Mariner Ltd Limited Liability Company. Deutsche Bank Ag holds 0% in Phillips 66 Partners LP (NYSE:PSXP) or 94,040 shares. Fdx invested in 6,404 shares or 0.01% of the stock. Advisory Rech reported 1.16 million shares stake. Zimmer Prtn Lp reported 62,813 shares stake. Stifel holds 13,359 shares or 0% of its portfolio. 88,229 are owned by Raymond James Fincl Advisors. Beaumont Fin Ptnrs Ltd Llc holds 0.03% in Phillips 66 Partners LP (NYSE:PSXP) or 4,384 shares. The Illinois-based Geneva Advisors Limited Liability has invested 0.05% in Phillips 66 Partners LP (NYSE:PSXP). Center Coast Capital Advisors L P reported 1.7% in Phillips 66 Partners LP (NYSE:PSXP).

Among 15 analysts covering Phillips 66 Partners (NYSE:PSXP), 12 have Buy rating, 0 Sell and 3 Hold. Therefore 80% are positive. Phillips 66 Partners has $81 highest and $50.0 lowest target. $63.93’s average target is 38.95% above currents $46.01 stock price. Phillips 66 Partners had 41 analyst reports since August 4, 2015 according to SRatingsIntel. Raymond James initiated it with “Outperform” rating and $72 target in Thursday, April 21 report. Barclays Capital upgraded the stock to “Buy” rating in Tuesday, July 18 report. Stifel Nicolaus initiated it with “Buy” rating and $59 target in Thursday, August 18 report. The rating was maintained by Barclays Capital on Monday, October 30 with “Overweight”. The stock has “Overweight” rating by Morgan Stanley on Friday, November 17. JP Morgan maintained the shares of PSXP in report on Tuesday, March 15 with “Overweight” rating. The firm has “Outperform” rating given on Monday, November 2 by RBC Capital Markets. Jefferies maintained it with “Hold” rating and $51.0 target in Monday, October 16 report. On Thursday, October 26 the stock rating was maintained by Stifel Nicolaus with “Buy”. Stifel Nicolaus maintained the shares of PSXP in report on Monday, October 30 with “Buy” rating.

Analysts await Phillips 66 Partners LP (NYSE:PSXP) to report earnings on February, 2. They expect $0.89 earnings per share, up 36.92% or $0.24 from last year’s $0.65 per share. PSXP’s profit will be $108.15 million for 12.92 P/E if the $0.89 EPS becomes a reality. After $0.51 actual earnings per share reported by Phillips 66 Partners LP for the previous quarter, Wall Street now forecasts 74.51% EPS growth.

C. R. Bard, Inc., together with its subsidiaries, designs, makes, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company has market cap of $24.21 billion. The firm offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It has a 43.81 P/E ratio. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Stephen Andrade




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: